Study on the Impact of Trastuzumab Combined with Pertuzumab on the Survival of HER2-Positive Breast Cancer Patients
Wu Xianghu
Yu Yang
Xie Juan
Abstract：Objective:To investigate the effect of trastuzumab in combination with pertuzumab on the survival outcomes of patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer.Methods:A cohort of 100 HER2-positive breast cancer patients treated at our hospital between March 2020 and March 2023 was included in this study.The patients were randomly divided into the trastuzumab group(n=50)and the combined group(n=50)by envelope drawing method.The trastuzumab group was treated with trastuzumab,while the combined group received trastuzumab and pertuzumab.The clinical efficacy,tumor-related indicators,adverse reactions,and survival rates of the two groups were compared after treatment.Results:After treatment,the disease control rate and overall efficacy rate of the combined group were higher than those of the trastuzumab group(P＜0.05).The levels of carbohydrate antigen 125(CA125),carbohydrate antigen 153(CA153),and carcinoembryonic antigen(CEA)in the combined group were lower than those in the trastuzumab group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups,with statistically significant differences(P＞0.05).The progression-free survival(PFS)and overall survival(OS)of the combined group were higher than those of the trastuzumab group,with statistically significant differences(P＜0.05).Conclusion:The combination of trastuzumab and pertuzumab has a significant impact on the survival of HER2-positive breast cancer patients.
Keywords：TrastuzumabPertuzumabHER2-positive breast cancerSurvival period
Publication Date：2026-01-25
Online Publishing Date：2026-03-23(First online date of this platform, not the publication date of the document)
Pages：3( 194-196 )